ZyVersa Therapeutics Inc - ZVSA STOCK NEWS

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a biopharmaceutical company, has announced that CEO Stephen C. Glover will present at the Planet MicroCap Showcase 2023 in Las Vegas. The event is scheduled for April 26, 2023, at 2:00 PM PDT at Horseshoe Hotel & Casino. Glover will discuss the development of two key product candidates: Cholesterol Efflux Mediator™ VAR 200, aimed at addressing renal diseases, and Inflammasome ASC Inhibitor IC 100, targeting various CNS and inflammatory diseases. ZyVersa is focused on creating first-in-class therapies for unmet medical needs in renal and inflammatory diseases. Stakeholders are encouraged to schedule one-on-one meetings with Glover through the conference portal to learn more about the company’s innovative pipeline.

ZyVersa Therapeutics (NASDAQ: ZVSA) announced a significant scientific publication in the peer-reviewed journal Brain Pathology, focusing on the inflammasome ASC Inhibitor IC 100. This research, conducted by experts from the University of Miami, indicates that increased expression of inflammasome proteins like NLRP1 and NLRP3 occurs early in Alzheimer's disease (AD). The findings suggest that IC 100 could serve as a diagnostic tool and an early therapeutic intervention for AD by identifying neurons affected by the disease.

The study highlights the correlation between ASC expression and biomarkers of AD progression (Aβ and p-tau). ZyVersa's preclinical data indicate that IC 100 may alleviate chronic neuroinflammation, which plays a crucial role in AD progression.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced a significant corporate update, following its business combination with Larkspur Health Acquisition Corp. in December 2022. The company has initiated trading on Nasdaq and is advancing its lead clinical candidate, Cholesterol Efflux Mediator™ VAR 200, with an investigator-initiated trial planned for FSGS and other renal indications in Q4 2023. ZyVersa also prepares for an IND submission for inflammasome ASC inhibitor IC 100 in Q2 2024, supported by recent promising preclinical data. Despite not generating revenue since inception, the firm anticipates 2023 will be pivotal for growth.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced the grant of inducement equity awards to two newly hired employees, effective March 8, 2023. The grants comprise nonqualified stock options to purchase a total of 13,000 shares at an exercise price of $2.26 per share, aligning with the closing price on that date. These options will vest in three annual installments starting March 8, 2024, contingent upon continued employment. ZyVersa focuses on developing first-in-class drugs for renal and inflammatory diseases, with products like VAR 200 targeting rare kidney diseases. The company emphasizes a commitment to addressing significant unmet medical needs.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) has announced the addition of Dr. Richard J. Glassock to its Renal Scientific Advisory Board, enhancing its commitment to developing innovative treatments for renal diseases. Dr. Glassock, an expert in glomerular disease, joins a team of distinguished advisors to advance the clinical development of VAR 200, a phase 2a-ready drug aimed at reducing renal lipid accumulation. The drug targets orphan kidney diseases, including focal segmental glomerulosclerosis (FSGS) and has shown promise in preclinical studies. ZyVersa aims to leverage this expertise to enhance its drug therapies for significant unmet medical needs in renal and inflammatory diseases.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced that CEO Stephen C. Glover will speak at the 33rd Annual Oppenheimer Healthcare Conference held virtually from March 13-15, 2023. During the event, Glover will discuss the development status of their Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, aimed at treating renal diseases, and the inflammasome ASC inhibitor IC 100, targeting various CNS and inflammatory diseases. The conference aims to showcase ZyVersa's innovative product pipeline and potential for stockholder value. To learn more, a virtual one-on-one meeting with Glover can be arranged via the conference portal.

ZyVersa Therapeutics announced that CEO Stephen C. Glover will present key updates on its drug candidates during a fireside chat at the 35th Annual Roth Conference on March 14, 2023. The discussion will focus on the Cholesterol Efflux Mediator™ VAR 200, aimed at treating renal diseases, and the inflammasome ASC inhibitor IC 100, which targets various inflammatory diseases. The event will take place at The Ritz Carlton, Laguna Niguel, California.

ZyVersa, listed on Nasdaq as ZVSA, specializes in developing innovative therapies for conditions with significant unmet medical needs.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) recently highlighted research published in Translational Research, revealing that traumatic brain injury (TBI) enhances inflammasome activation in Alzheimer's disease (AD), worsening cognitive outcomes. It notes that individuals with a history of moderate TBI are 2.3 times more likely to develop AD, according to CDC data. The study asserts that IC 100, an inflammasome ASC inhibitor, significantly reduces this inflammatory response in AD models post-TBI. ZyVersa aims to leverage this data to advance its therapeutic approach targeting inflammasome-related neurological disorders.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced on January 27, 2023, the grant of an inducement equity award to its new Chief Medical Officer, Dr. Pablo Guzman. The grant includes a nonqualified stock option for 100,000 shares at an exercise price of $2.11 per share, the closing price on January 25, 2023. This award, approved by the Board’s Compensation Committee, vests in three equal installments over three years, contingent on Dr. Guzman's continued employment. ZyVersa focuses on developing first-in-class drugs for renal and inflammatory diseases, with notable projects including VAR 200 and IC 100.